How to buy Celldex Therapeutics stock | $27.95

Celldex Therapeutics, Inc is a biotechnology business based in the US. Celldex Therapeutics shares (CLDX) are listed on the NASDAQ and all prices are listed in US Dollars. Celldex Therapeutics employs 123 staff and has a trailing 12-month revenue of around 0.00.

Celldex Therapeutics stock price (NASDAQ: CLDX)

Use our graph to track the performance of CLDX stocks over time.

Celldex Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$27.95
52-week range	$9.66 - $46.42
50-day moving average	$35.55
200-day moving average	$27.47
Wall St. target price	$51.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.74

Buy Celldex Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Celldex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Celldex Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celldex Therapeutics price performance over time

Historical closes compared with the close of $27.95 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	-18.82%
3 months (2021-04-30)	-7.85%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Celldex Therapeutics financials

Revenue TTM	$5.4 million
Gross profit TTM	$-35,116,000
Return on assets TTM	-20.02%
Return on equity TTM	-45.84%
Profit margin	0%
Book value	$4.90
Market capitalisation	$2.1 billion

TTM: trailing 12 months

Shorting Celldex Therapeutics shares

There are currently 3.3 million Celldex Therapeutics shares held short by investors – that's known as Celldex Therapeutics's "short interest". This figure is 19% up from 2.8 million last month.

There are a few different ways that this level of interest in shorting Celldex Therapeutics shares can be evaluated.

Celldex Therapeutics's "short interest ratio" (SIR)

Celldex Therapeutics's "short interest ratio" (SIR) is the quantity of Celldex Therapeutics shares currently shorted divided by the average quantity of Celldex Therapeutics shares traded daily (recently around 1.5 million). Celldex Therapeutics's SIR currently stands at 2.24. In other words for every 100,000 Celldex Therapeutics shares traded daily on the market, roughly 2240 shares are currently held short.

However Celldex Therapeutics's short interest can also be evaluated against the total number of Celldex Therapeutics shares, or, against the total number of tradable Celldex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celldex Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Celldex Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1009% of the tradable shares (for every 100,000 tradable Celldex Therapeutics shares, roughly 101 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Celldex Therapeutics.

Find out more about how you can short Celldex Therapeutics stock.

Celldex Therapeutics share dividends

We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.

Have Celldex Therapeutics's shares ever split?

Celldex Therapeutics's shares were split on a 1:15 basis on 10 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.

Celldex Therapeutics share price volatility

Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $9.66 up to $46.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 3.0588. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Celldex Therapeutics overview

Celldex Therapeutics, Inc. , a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University.

Frequently asked questions

What percentage of Celldex Therapeutics is owned by insiders or institutions?
Currently 4.483% of Celldex Therapeutics shares are held by insiders and 76.165% by institutions. How many people work for Celldex Therapeutics?
Latest data suggests 123 work at Celldex Therapeutics. When does the fiscal year end for Celldex Therapeutics?
Celldex Therapeutics's fiscal year ends in December. Where is Celldex Therapeutics based?
Celldex Therapeutics's address is: Perryville III Building, Hampton, NJ, United States, 08827 What is Celldex Therapeutics's ISIN number?
Celldex Therapeutics's international securities identification number is: US15117B2025 What is Celldex Therapeutics's CUSIP number?
Celldex Therapeutics's Committee on Uniform Securities Identification Procedures number is: 053491106